Amplifon investors came into this earnings season on the back foot. The stock has slipped about 8% over the past month to €11.17, even as expectations for hearing care demand and earnings growth remained elevated.
The Q3 2026 release put profitability under the spotlight. Quarterly net income of €9.4m and basic earnings per share of €0.028 looked thin against a P/E of 39.4x and a trailing net margin of 3.1%. In the short term, that combination can pressure the share price. Over a longer horizon, it forces a harder look at whether the current valuation still matches the earnings power investors expect.
Love Amplifon’s exposure to long term hearing care demand, but uneasy about paying a 39.4x P/E for thin 3.1% net margins? Take a look at our screener of companies with stronger profitability profiles and more robust earnings power through the list of solid balance sheet and fundamentals stocks (203 results).
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs Q3 2025): €575.0m vs €563.3m (modest top line increase)
-
Net Income (Q3 2026 vs Q3 2025): €9.4m vs €6.3m (profit level improved)
-
Basic EPS (Q3 2026 vs Q3 2025): €0.028 vs €0.02859 (broadly flat earnings per share)
-
Adjusted EBITDA Margin (Q3 2026 vs Q3 2025): 20.0% vs 19.1% (about +90 bps margin uplift, where bps means basis points)
Tired of wading through dense earnings releases and rows of numbers to figure out what Amplifon is really worth? Get a clear visual read on the stock’s valuation, together with the full context of its financial profile, in the company report for Amplifon.
Amplifon’s Execution Story Meets Early Milestones
Amplifon’s bullish story hinges on execution turning into durable market share gains and richer margins rather than a surge in hearing care demand.
“The main requirement for this view is successful execution of the GN Hearing vertical integration and Fit4Growth store optimisation so that the planned cost synergies and margin improvement actually flow through.”
On that score, the latest quarter gives partial confirmation. Organic growth of 3.6% and a 90 bps lift in adjusted EBITDA margin show Fit4Growth feeding through to profitability. Stronger free cash flow and lower net debt to EBITDA also support the idea that Amplifon is preparing the balance sheet for GN Hearing integration.
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.
Amplifon Bear Case: Revenue Sacrifice Still Bites
Bearish investors argue that Amplifon’s margin plan may come at the expense of future sales momentum and execution around GN Hearing.
